Metastasis-free Survival

PSA Doubling Time – A Significant Prognostic Marker 

PSA Doubling Time – A Significant Prognostic Marker 

Shorter prostate-specific antigen doubling time was significantly associated with shorter metastasis-free survival and overall survival.

The development of metastasis was associated with a 3-fold higher risk of death.

The onset of non-metastatic castrate-resistant prostate cancer and metastatic castrate-resistant prostate cancer was associated with substantial cost increases.

Xtandi Improves Metastasis Free Survival In Men Who Are Castrate Resistant And Do Not Have Metastasis

It was announced that Enzalutamide (Xtandi) is the first androgen receptor-inhibitor to demonstrate a statistically significant improvement in metastasis-free survival (MFS) in men who have castrate resistant prostate cancer but do not have any confirmed metastases.